Deborah A. Hall

Deborah A. Hall

Auto-generated profile, based on publicly available information

Deborah A. Hall

Department of Neurological Sciences Rush University Medical Center Chicago IL

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2014 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
DHDeborah A Hall
Deborah A Hall
RBRachael C Birch
Rachael C Birch
MAMathieu Anheim
Mathieu Anheim
AJAia E Jønch
Aia E Jønch
EPElizabeth Pintado
Elizabeth Pintado
MLMaureen A Leehey
Maureen A Leehey
This paper summarizes key emerging issues in fragile X-associated tremor/ataxia syndrome (FXTAS) as presented at the First International Conference on the FMR1 Premutation: Basic Mechanisms & Clinical Involvement in 2013.

25 January 2022 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
GPGian Pal
Gian Pal
GMGraziella Mangone
Graziella Mangone
EHEmily J. Hill
Emily J. Hill
BOBichun Ouyang
Bichun Ouyang
YLYuanqing Liu
Yuanqing Liu
CGChristopher G. Goetz
Christopher G. Goetz

21 September 2023 in Cells
Verified
Journal Article
Open access
PDF file
FTFlora Tassone
Flora Tassone
DPDragana Protic
Dragana Protic
EAEmily G. Allen
Emily G. Allen
AAAlison D. Archibald
Alison D. Archibald
ABAnna Baud
Anna Baud
RHRandi Hagerman
Randi Hagerman
The premutation of the fragile X messenger ribonucleoprotein 1 (FMR1) gene is characterized by an expansion of the CGG trinucleotide repeats (55 to 200 CGGs) in the 5’ untranslated region and increased levels of FMR1 mRNA. Molecular mechanisms leading to fragile X-premutation-associated conditions (FXPAC) include cotranscriptional R-loop formations, FMR1 mRNA toxicity through both RNA gelation into nuclear foci and sequestration of various CGG-repeat-binding proteins, and the repeat-associated non-AUG (RAN)-initiated translation of potentially toxic proteins. Such molecular mechanisms contribute to subsequent consequences, including mitochondrial dysfunction and neuronal death. Clinically, premutation carriers may exhibit a wide range of symptoms and phenotypes. Any of the problems associated with the premutation can appropriately be called FXPAC. Fragile X-associated tremor/ataxia syndrome (FXTAS), fragile X-associated primary ovarian insufficiency (FXPOI), and fragile X-associated neuropsychiatric disorders (FXAND) can fall under FXPAC. Understanding the molecular and clinical aspects of the premutation of the FMR1 gene is crucial for the accurate diagnosis, genetic counseling, and appropriate management of affected individuals and families. This paper summarizes all the known problems associated with the premutation and documents the presentations and discussions that occurred at the International Premutation Conference, which took place in New Zealand in 2023.

1 January 2018
Verified
Book Chapter
Closed access
DHDeborah A Hall
Deborah A Hall
EBElizabeth Berry-Kravis
Elizabeth Berry-Kravis

28 October 2016 in Journal of NeuroEngineering and Rehabilitation
Verified
Journal Article
Open access
PDF file
GPGian Pal
Gian Pal
JOJoan O’keefe
Joan O’keefe
ERErin Robertson-Dick
Erin Robertson-Dick
BBBryan Bernard
Bryan Bernard
SASharlet Anderson
Sharlet Anderson
DHDeborah Hall
Deborah Hall
Our primary objective was to determine the relationship between global cognitive function and specific domains of gait and balance in a cohort of Parkinson’s disease (PD) subjects. In a secondary analysis, we determined whether specific cognitive domains correlated with gait and balance performance. Fourteen PD subjects (mean age 61.1 ± 7.8 years) were recruited from the Rush University Medical Center Movement Disorders clinic. Subjects underwent clinical assessment using the motor subsection of the Unified Parkinson’s Disease Rating Scale (UPDRS) followed by quantitative gait and balance assessments using the APDM Mobility Lab™ system (Mobility Lab, APDM Inc., Portland, OR). Subjects completed global cognitive testing using the Mattis Dementia Rating Scale (MDRS) as well as domain specific cognitive measures. Spearman’s rho was used to assess correlations between cognitive measures and gait and balance function, with False Discovery Rate (FDR) correction for multiple comparisons. Global cognitive function had the strongest correlation with stride velocity (r = 0.816, p = 0.001), turn duration (r = −0.806, p = 0.001), number of steps to turn (r = −0.830, p = 0.001), and mean velocity of postural sway in the medio-lateral direction (r = −0.726, p = 0.005). A significant correlation was found between processing speed and two turning measures (turn duration, r = −0.884, p = 0.001; number of steps to turn, r = −0.954, p < 0.001), but no other associations were found between specific cognitive domains and gait domains. This pilot study provides preliminary data regarding the association between global cognitive function and pace-related measures of gait, turning, and postural sway. Furthermore, reduced processing speed was found to be associated with difficulty in performing turns.

9 February 2023 in Annals of Neurology
Verified
Journal Article
Open access
BBBastiaan R. Bloem
Bastiaan R. Bloem
EPErik Post
Erik Post
DHDeborah A. Hall
Deborah A. Hall
It is challenging to reliably assess the motor features of Parkinson's disease in real‐time. This has motivated the search for new digital outcomes that can objectively and remotely measure the severity of parkinsonian motor impairments over an extended period of time. The United States Food and Drug Administration (FDA) has recently granted a 510(k) clearance to the Rune Labs Kinematics System, an ambulatory, smartwatch‐based monitoring system to remotely track tremor and dyskinesias in persons with Parkinson's disease. The FDA clearance means that this new digital approach can be regarded as being safe for use in daily practice, with acceptable correlations to clinically based measures. However, the immediate implications for clinicians are limited, because it remains to be demonstrated whether the digital signals correlate well to clinically meaningful outcomes at patient level. The impact on research is also restricted for now, as more validation studies are needed before this new digital approach can be used as primary or secondary endpoint in clinical trials. ANN NEUROL 2023;93:681–685